about
The N-terminal extension is essential for the formation of the active dimeric structure of liver peroxisomal alanine:glyoxylate aminotransferaseDisease recurrence in paediatric renal transplantationPharmacologic rescue of an enzyme-trafficking defect in primary hyperoxaluria 1.Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation.Primary hyperoxaluria.Development of a phenotypic high-content assay to identify pharmacoperone drugs for the treatment of primary hyperoxaluria type 1 by high-throughput screening.A mutation creating an out-of-frame alternative translation initiation site in the GRHPR 5'UTR causing primary hyperoxaluria type II.Primary hyperoxaluria type 1: still challenging!Four of the most common mutations in primary hyperoxaluria type 1 unmask the cryptic mitochondrial targeting sequence of alanine:glyoxylate aminotransferase encoded by the polymorphic minor allele.New treatment strategies for proliferative lupus nephritis: keep children in mind!Primary hyperoxaluria type 1: strategy for organ transplantation.Survey of first-year medical students to assess their knowledge and attitudes toward organ transplantation and donation.Effects of alanine:glyoxylate aminotransferase variants and pyridoxine sensitivity on oxalate metabolism in a cell-based cytotoxicity assay.Metabolism of (13)C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase.Bone metabolism in oxalosis: a single-center study using new imaging techniques and biomarkers.Tacrolimus nephrotoxicity: beware of the association of diarrhea, drug interaction and pharmacogenetics.Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome.Hyperuricemia after liver transplantation in children.Pyridoxamine and pyridoxal are more effective than pyridoxine in rescuing folding-defective variants of human alanine:glyoxylate aminotransferase causing primary hyperoxaluria type I.Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1.Factors influencing clinical outcome in patients with primary hyperoxaluria type 1Hyperoxalurie primitiveEndpoints for Clinical Trials in Primary Hyperoxaluria
P50
Q24300662-2F190E48-740D-4352-83B8-034041880C44Q24645234-0A12BEC8-EF33-4CCA-956C-5A94719376B4Q34407663-F15FA231-C290-409B-B08B-22C4F67E99F6Q34695450-B0A7CE4A-9769-495A-AAD4-7214C3C1B0A5Q35073045-ECE37BE2-B840-4F0F-820C-106A63AD3301Q35566939-95603FFA-A83E-4477-9A84-08F039E9BE91Q35625168-03EDB1C7-A365-439D-A7A8-FED9DF461470Q36524018-A5115593-AA96-4395-A7A2-0DCB8A935A04Q36562007-B60D604D-73E8-4435-9E4D-9C23E660DCCAQ36915693-147C279D-747A-4657-B0CD-07E57EE0E1B0Q37781989-ED74C490-94CD-4D67-8938-55BD34E001D0Q39991637-50FAEB42-555C-4CAA-B24F-B35EFC16149DQ40015456-E6D16BEE-228A-4AC9-B8D3-2D608EC2D47FQ43098007-C0025DBD-5C0D-4D77-8EA9-7BC80BAE53FEQ43137925-0E5A6D77-9CCD-4286-A092-49E816E931B4Q43187743-D1EA1054-7694-4C93-BA90-ECACA080974EQ43218013-E1531DBB-9995-4766-ADBA-2F4DDD3D53CFQ46552997-9D70225A-BCC0-43F8-823B-5FD778D59CCDQ50576688-F6219A73-1118-4487-867A-FD3355FA595EQ50748176-8F37A4C3-2F87-4D8A-AC0B-39670FDF1C62Q63441475-B8F62961-334E-497D-9E66-E34832136166Q63441480-8F12F436-3E79-4D63-A649-5013FF9610C8Q90280443-D1E3BB5F-1131-41D1-8D20-2B9F73C5FB4B
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sonia Fargue
@ast
Sonia Fargue
@en
Sonia Fargue
@es
Sonia Fargue
@nl
Sonia Fargue
@sl
type
label
Sonia Fargue
@ast
Sonia Fargue
@en
Sonia Fargue
@es
Sonia Fargue
@nl
Sonia Fargue
@sl
prefLabel
Sonia Fargue
@ast
Sonia Fargue
@en
Sonia Fargue
@es
Sonia Fargue
@nl
Sonia Fargue
@sl
P106
P21
P31
P496
0000-0001-7451-7481